{"filings":[{"id":94348,"accession_number":"0001645113-26-000043","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure Q1 net revenue $174M (+12% YoY); raises FY2026 guidance; Optune Pax launch","event_type":"earnings","confidence":"high","bullets":["Net loss of $71.1M ($0.62 per share); Adjusted EBITDA of -$0.3M.","Gross margin improved to 78% (from 75%) on lower array costs.","Optune Pax FDA approved for locally advanced pancreatic cancer; 169 prescriptions, 83 active patients as of March 31, 2026.","FY2026 revenue guidance raised to $690M-$710M (from $675M-$705M); Adj. EBITDA guidance narrowed to -$15M-$0M.","PANOVA-4 Phase 2 met primary endpoint with 74% disease control rate vs 48% historical control."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":174055000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94346,"accession_number":"0001645113-26-000038","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K/A","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NovoCure discloses CEO Frank Leonard's pay: CHF 750K base, 90% target bonus, enhanced severance","event_type":"leadership","confidence":"high","bullets":["Base salary of CHF 750,000 and target annual bonus of 90% of base (CHF 675,000).","Eligible for equity awards under 2024 Omnibus Incentive Plan; relocation and tax indemnification provided.","Severance on qualifying termination: 100% base salary; within 12 months post-change-in-control: 200% base + 200% target bonus plus full equity vesting.","Non-compete covenant for 12 months after termination; perpetual non-disparagement.","Amendment filed to supplement Dec. 1, 2025 8-K; compensation details now finalized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94347,"accession_number":"0001645113-26-000026","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NovoCure names Dr. Uri Weinberg CMO, adds CHF 5k/month stipend","event_type":"leadership","confidence":"high","bullets":["Dr. Uri Weinberg, previously Chief Innovation Officer, also appointed Chief Medical Officer effective April 7, 2026.","Monthly salary increased by CHF 5,000 (gross) for the duration of the CMO assignment.","Stipend not included in annual incentive payment (AIP); all other terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106631,"accession_number":"0001645113-26-000023","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novocure PANOVA-4 trial meets primary endpoint; DCR 74.4% vs 48% historical control in mPDAC","event_type":"other_material","confidence":"high","bullets":["PANOVA-4 met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431), 1-sided p<0.001.","Secondary endpoints: ORR 34.6% (95% CI 24.2%-46.2%), median OS 9.7 months (95% CI 7.9-12.7 months).","TTFields therapy with atezolizumab and gem/nab-pac well-tolerated; safety consistent with prior studies.","Novocure plans to present further PANOVA-4 data at a future scientific forum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106630,"accession_number":"0001645113-26-000018","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure reports Q4 2025 revenues up 8% to $174M; FDA approves Optune Pax for pancreatic cancer","event_type":"other_material","confidence":"high","bullets":["FDA approved Optune Pax for locally advanced pancreatic cancer in Feb 2026; expands addressable market significantly.","Q4 2025 net revenue $174.4M (+8% YoY); full year $655.4M (+8%). Q4 net loss $24.5M ($0.22 loss per share).","2026 guidance: revenue $675-705M; Adjusted EBITDA ($20M)-$0M; Optune Lua/Pax revenue $15-25M.","Frank Leonard appointed CEO Dec 2025; CMO Nicolas Leupin resigned Feb 2026; CMS billing privileges reinstated.","Active patients on TTFields therapy globally totaled 4,620 at Dec 31, 2025; GBM prescriptions up 6%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106629,"accession_number":"0001645113-26-000013","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CMS rescinds retroactive revocation of Novocure's Medicare billing privileges","event_type":"regulatory","confidence":"high","bullets":["CMS revoked billing privileges retroactive to Dec 17, 2025; cited administrative re-validation issue, not substantive failure.","On Feb 24, 2026, CMS rescinded revocation and reinstated privileges retroactively to Dec 17, 2025.","Company continued patient services during revocation and expects no impact on revenue recognition.","Revocation letter dated Jan 29, 2026; resolution achieved within one month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106628,"accession_number":"0001645113-26-000010","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA Approves Novocure's Optune Pax for Locally Advanced Pancreatic Cancer","event_type":"regulatory","confidence":"high","bullets":["FDA approval based on Phase 3 PANOVA-3 trial in 571 patients with locally advanced pancreatic cancer.","Median overall survival improved to 16.2 months vs 14.2 months (HR 0.82, p=0.039).","Time to pain progression extended by 6.1 months (15.2 vs 9.1 months).","First new treatment approved for locally advanced pancreatic cancer in nearly 30 years.","Optune Pax well-tolerated; most adverse events were mild-to-moderate skin reactions under arrays."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106627,"accession_number":"0001645113-26-000007","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NovoCure receives CMS billing revocation; expects ~$13M/month revenue impact until reinstatement","event_type":"regulatory","confidence":"high","bullets":["CMS revoked NovoCure's billing privileges retroactive to Dec 17, 2025 due to an administrative re-validation process issue.","Company estimates approximately $13 million per month in lost revenue from CMS payors until privileges are reinstated.","NovoCure has filed a Corrective Action Plan and expects reinstatement, but cannot predict timing with certainty.","Company continues to provide services to existing and new patients; will attempt to bill for services during reinstatement.","Financial impact and ultimate outcome cannot be determined at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106626,"accession_number":"0001645113-26-000003","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NovoCure reports record FY2025 revenue $655M (+8% YoY); appoints Frank Leonard as CEO","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2025 net revenue $655.4M (+8% YoY); Q4 revenue $174.4M (+8% YoY).","Cash and investments $448.3M after repaying $561M convertible notes due Nov 2025.","Active TTFields patients reached 4,620 globally; Optune Gio prescriptions +6% in Q4.","Frank Leonard, previously President, appointed CEO in December 2025.","Filed PMA for TTFields in brain metastases from NSCLC; topline data expected Q1-Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":655353000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122958,"accession_number":"0001645113-25-000045","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Novocure appoints President Frank Leonard as CEO; Ashley Cordova resigns","event_type":"leadership","confidence":"high","bullets":["Ashley Cordova resigned as CEO and director effective Nov 30, 2025; no disagreement related to operations.","Frank Leonard, previously President, becomes CEO effective Dec 1, 2025; he joined Novocure in 2010.","Cordova enters garden leave through May 31, 2026, with salary, benefits, bonus, and CHF 375,000 cash payment.","Leonard led global business operations since Jan 2024 and prior innovation/product development.","Executive Chairman William Doyle cites Leonard as ideal for upcoming transformative milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122957,"accession_number":"0001645113-25-000043","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NovoCure Q3 revenue $167M (+8% YoY), net loss $37.3M; PMA for pancreatic cancer under review","event_type":"earnings","confidence":"high","bullets":["Net revenues of $167.2M, up 8% YoY; US contributed $96.6M, Germany $20.3M, France $19.6M, Japan $9.4M.","Net loss of $37.3M ($0.33 loss per share); adjusted EBITDA of $(3.0)M; gross margin 73% vs 77% YoY.","4,416 active patients globally as of Sept 30, 2025; Optune Gio prescriptions up 7% to 1,675.","PMA for TTFields in locally advanced pancreatic cancer accepted by FDA; PMA for brain metastases from NSCLC planned Q4 2025.","Cash and short-term investments $1,033.5M; Spain coverage for Optune Gio; Japan approval for Optune Lua with PD-1/L1."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":481003000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139664,"accession_number":"0001645113-25-000037","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Japan MHLW approves Novocure's Optune Lua for advanced NSCLC","event_type":"regulatory","confidence":"high","bullets":["Japan MHLW approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors in advanced/recurrent NSCLC after platinum-based chemo.","Approval based on Phase 3 LUNAR trial: median OS 13.2 vs 9.9 months (3.3-month improvement, p=0.04).","In PD-1/PD-L1 subgroup, median OS 19.0 vs 10.8 months (8.2-month improvement, p=0.02).","Optune Lua is a wearable TTFields device; device-related AEs were mostly grade 1-2 skin reactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139663,"accession_number":"0001645113-25-000032","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NovoCure terminates LUNAR-4 phase 2 trial for metastatic NSCLC, cites real-world evidence alternative","event_type":"other_material","confidence":"high","bullets":["Novocure GmbH terminated the LUNAR-4 phase 2 trial of Tumor Treating Fields with pembrolizumab for metastatic non-small cell lung cancer.","Decision based on availability of real-world evidence to achieve trial objectives without an interventional clinical study.","Termination is not related to any safety concerns; no impact on other Novocure studies.","Trial targeted patients previously treated with PD-1/PD-L1 inhibitor and platinum-based chemotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139662,"accession_number":"0001645113-25-000030","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NovoCure Q2 2025 revenue $158.8M (+6% YoY), net loss $40.1M; plans pancreatic cancer PMA in Q3","event_type":"earnings","confidence":"high","bullets":["Net revenues $158.8M, up 6% YoY; net loss $40.1M ($0.36 loss per share); adjusted EBITDA -$9.9M.","4,331 active patients on TTFields globally; Optune Gio active patients up 7% YoY.","Phase 3 PANOVA-3 pancreatic cancer trial met primary endpoint; PMA submission to FDA planned Q3 2025.","PMA for brain metastases from NSCLC planned H2 2025; TRIDENT and PANOVA-4 readouts expected H1 2026.","Cash and investments $911.5M as of June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":313799000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157242,"accession_number":"0001645113-25-000011","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NovoCure shareholders elect 11 directors, approve ESPP; President awarded 179,426 RSUs","event_type":"other_material","confidence":"high","bullets":["Shareholders elected all 11 director nominees with >81M votes each; 92.98M shares represented (~83.4%).","Say-on-pay approved: 80.6M for, 2.0M against, ~10M broker non-votes.","2025 Employee Share Purchase Plan approved: 82.0M for, 0.68M against; reserves 6,507,843 shares (less prior plan shares).","Francis Leonard appointed President, Novocure and awarded 179,426 RSUs vesting in two equal annual installments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157241,"accession_number":"0001645113-25-000010","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Phase 3 PANOVA-3 trial meets primary endpoint; median OS improved to 16.2 vs 14.2 months (HR 0.82, p=0.039)","event_type":"other_material","confidence":"high","bullets":["Median overall survival 16.2 months with TTFields + GnP vs 14.2 months for GnP alone; HR 0.82, p=0.039.","One-year survival rate 68.1% vs 60.2% (p=0.029).","Median pain-free survival 15.2 months vs 9.1 months; 6.1-month extension (HR 0.74, p=0.027).","TTFields therapy well-tolerated with mild to moderate skin adverse events; no new safety signals.","Company plans to file for FDA PMA approval in second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}